Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Wild-type (senile) amyloidosis epidemiology and demographics

Introduction

Overview

Overview

The incidence of amyloidosis is approximately 1.2 per 100,000 individuals per year worldwide. The actual incidence of wild-type (senile) amyloidosis in particular is unknown. The mortality rate of systemic amyloidosis is approximately 100 per 100,000 deaths in developed countries. Patients with wild-type (senile) amyloidosis are almost always elderly (65 years of age or older). There is no racial predilection to wild-type (senile) amyloidosis. Men are traditionally more commonly affected by wild-type (senile) amyloidosis than women.

Epidemiology and Demographics

Epidemiology and Demographics

Incidence

  • The incidence of amyloidosis is approximately 1.2 per 100,000 individuals per year worldwide.[1]
  • The actual incidence of wild-type (senile) amyloidosis in particular is unknown.

Prevalence

  • The prevalence of wild-type (senile) amyloidosis has not been determined.
  • It is estimated that approximately 25% of the people beyond the age of 80 have cardiac TTR deposition.[2]

Mortality rate

  • The mortality rate of systemic amyloidosis is approximately 100 per 100,000 deaths in developed countries.[3]

Age

  • Patients with wild-type (senile) amyloidosis are almost always elderly (65 years of age or older).

Race

  • There is no racial predilection to wild-type (senile) amyloidosis.

Gender

  • Men are traditionally more commonly affected by wild-type (senile) amyloidosis than women.[4]
References

References

  1. ↑ Khan MF, Falk RH (November 2001). “Amyloidosis”. Postgrad Med J. 77 (913): 686–93. PMC 1742163. PMID 11677276.
  2. ↑ G. G. 3rd Cornwell, W. L. Murdoch, R. A. Kyle, P. Westermark & P. Pitkanen (1983). “Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation”. The American journal of medicine. 75 (4): 618–623. doi:10.1016/0002-9343(83)90443-6. PMID 6624768. Unknown parameter |month= ignored (help)
  3. ↑ Pepys MB (2006). “Amyloidosis”. Annu. Rev. Med. 57: 223–41. doi:10.1146/annurev.med.57.121304.131243. PMID 16409147.
  4. ↑ Belinda Ng, Lawreen H. Connors, Ravin Davidoff, Martha Skinner & Rodney H. Falk (2005). “Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis”. Archives of internal medicine. 165 (12): 1425–1429. doi:10.1001/archinte.165.12.1425. PMID 15983293. Unknown parameter |month= ignored (help)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2]